These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 13678864)

  • 1. Candesartan and heart failure: the allure of CHARM.
    White HD
    Lancet; 2003 Sep; 362(9386):754-5. PubMed ID: 13678864
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H; Komuro I
    Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    McKelvie RS
    J Hypertens Suppl; 2006 Mar; 24(1):S9-13. PubMed ID: 16601580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CHARM programme raises the profile of candesartan cilexetil in the treatment of chronic health failure.
    Cardiovasc J S Afr; 2004; 15(1):42-3. PubMed ID: 15095753
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
    McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
    Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [AT1 blockers against heart failure. The charm of polypharmacy].
    MMW Fortschr Med; 2003 Sep; 145(38):6. PubMed ID: 14603670
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical study of the month. The CHARM study].
    Kulbertus H
    Rev Med Liege; 2003 Oct; 58(10):646-52. PubMed ID: 14677527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Candesartan reduces the risk of mortality and recurrence of chronic heart failure. Important results from the CHARM study].
    Persson H; Swedberg K
    Lakartidningen; 2004 Feb; 101(9):764-6. PubMed ID: 15045839
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial.
    Bhakta S; Dunlap ME
    Cleve Clin J Med; 2004 Aug; 71(8):665-73. PubMed ID: 15449762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CHARM].
    Momomura S
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():431-6. PubMed ID: 16981575
    [No Abstract]   [Full Text] [Related]  

  • 13. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Pocock S; Wang D; Wilhelmsen L; Hennekens CH
    Am Heart J; 2005 May; 149(5):939-43. PubMed ID: 15894981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
    Granger CB; McMurray JJ; Yusuf S; Held P; Michelson EL; Olofsson B; Ostergren J; Pfeffer MA; Swedberg K;
    Lancet; 2003 Sep; 362(9386):772-6. PubMed ID: 13678870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CHARM programme.
    Penston J
    Lancet; 2003 Nov; 362(9396):1678; author reply 1678-9. PubMed ID: 14630459
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
    Pfeffer MA; Swedberg K; Granger CB; Held P; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Yusuf S; Pocock S;
    Lancet; 2003 Sep; 362(9386):759-66. PubMed ID: 13678868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Benefits of candesartan in the treatment of symptomatic heart failure--CHARM programme].
    Umemoto S; Matsuzaki M
    Nihon Rinsho; 2004 Jan; 62(1):211-8. PubMed ID: 14737855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHARM shows improvement in NYHA functional class with candesartan.
    Cardiovasc J S Afr; 2004; 15(2):96-7. PubMed ID: 15148548
    [No Abstract]   [Full Text] [Related]  

  • 19. The CHARM programme.
    Pechlaner C
    Lancet; 2003 Nov; 362(9396):1675-6; author reply 1678-9. PubMed ID: 14630453
    [No Abstract]   [Full Text] [Related]  

  • 20. CHARM study in CHF patients with impaired LV function reinforces benefits of candesartan cilexetil (Atacand).
    Cardiovasc J S Afr; 2004; 15(5):252. PubMed ID: 15483738
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.